arrow
J

Jean-Sébastien Delisle

maisonneuve-rosemont
H指数:25
被引数:2,109

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Harnessing the promises of cell therapy; gene therapy; and regenerative medicine in Québec; Canada

更正:利用细胞疗法、基因疗法和再生医学在魁北克省加拿大的潜力。

2025-10-170
OAAI
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

同种异基因造血细胞移植在新型细胞疗法时代治疗B细胞淋巴瘤中的应用:来自一家三级加拿大中心的经验

2025-05-200
OA
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients
2025-01-010
OAAI
Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

异基因造血干细胞移植在新型细胞疗法时代中的应用:来自一家三级加拿大中心的经验

BLOOD
IF23.1
2024-11-050
PRE
CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax
2023-09-014
OA
Immunogenicity, Safety, and Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study
2023-04-138
OAAI
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge
2023-01-015
OAAI
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients

异基因干细胞移植受者三剂SARS-CoV-2疫苗方案后的安全性和免疫原性

2022-10-0127
OAAI
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective

在新疗法时代,自体和异基因造血干细胞移植治疗复发/难治性霍奇金淋巴瘤的真实世界结果: 加拿大的观点

2022-03-013
OAAI